X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5849) 5849
Book Review (930) 930
Publication (454) 454
Newsletter (279) 279
Newspaper Article (149) 149
Magazine Article (31) 31
Book Chapter (24) 24
Conference Proceeding (18) 18
Trade Publication Article (7) 7
Transcript (7) 7
Dissertation (2) 2
Paper (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (5089) 5089
humans (3567) 3567
thiazolidinediones (2844) 2844
male (2731) 2731
animals (2464) 2464
female (1934) 1934
thiazolidinediones - therapeutic use (1792) 1792
diabetes mellitus, type 2 - drug therapy (1714) 1714
thiazolidinediones - pharmacology (1667) 1667
hypoglycemic agents - therapeutic use (1640) 1640
diabetes (1329) 1329
rosiglitazone (1308) 1308
pioglitazone (1264) 1264
endocrinology & metabolism (1231) 1231
thiazolidinediones - administration & dosage (1223) 1223
middle aged (1220) 1220
rats (1203) 1203
insulin resistance (1120) 1120
type 2 diabetes (1118) 1118
mice (1116) 1116
hypoglycemic agents - pharmacology (1114) 1114
pharmacology & pharmacy (1085) 1085
hypoglycemic agents - administration & dosage (1079) 1079
ppar-gamma (888) 888
hypoglycemic agents - adverse effects (844) 844
adult (826) 826
aged (820) 820
thiazolidinediones - adverse effects (764) 764
ppar gamma - agonists (719) 719
insulin (713) 713
insulin-resistance (709) 709
drug therapy (681) 681
metformin (668) 668
glucose (660) 660
abridged index medicus (648) 648
drug therapy, combination (622) 622
risk factors (604) 604
troglitazone (585) 585
blood glucose - metabolism (569) 569
treatment outcome (561) 561
research (559) 559
ppar gamma - metabolism (552) 552
diabetes therapy (495) 495
metformin - therapeutic use (492) 492
diabetes mellitus, type 2 - blood (472) 472
hypoglycemic agents (471) 471
dose-response relationship, drug (467) 467
obesity (467) 467
expression (460) 460
disease models, animal (446) 446
inflammation (443) 443
diabetes mellitus (439) 439
administration, oral (437) 437
care and treatment (426) 426
thiazolidinedione (413) 413
medicine, general & internal (411) 411
dosage and administration (406) 406
rats, sprague-dawley (406) 406
risk (403) 403
insulin - blood (389) 389
thiazoles - pharmacology (377) 377
mellitus (374) 374
mice, inbred c57bl (367) 367
rats, wistar (362) 362
blood glucose - drug effects (355) 355
glycemic control (355) 355
activated-receptor-gamma (347) 347
analysis (347) 347
activated receptor-gamma (346) 346
gene-expression (344) 344
diabetes mellitus, type 2 - complications (340) 340
type-2 diabetes-mellitus (336) 336
time factors (334) 334
health aspects (332) 332
metabolism (332) 332
double-blind method (331) 331
internal medicine (331) 331
metformin - administration & dosage (328) 328
physiological aspects (321) 321
biochemistry & molecular biology (314) 314
medicine & public health (310) 310
dextrose (308) 308
oxidative stress (305) 305
chromans - pharmacology (293) 293
ligands (292) 292
cells, cultured (285) 285
drugs (284) 284
thiazoles - therapeutic use (283) 283
diabetes mellitus, type 2 - metabolism (282) 282
therapy (282) 282
metabolic syndrome (266) 266
adipose-tissue (259) 259
medicine, research & experimental (257) 257
article (252) 252
blood glucose - analysis (251) 251
sulfonylurea compounds - therapeutic use (248) 248
cardiac & cardiovascular systems (247) 247
complications and side effects (247) 247
insulin - therapeutic use (242) 242
double-blind (240) 240
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6153) 6153
German (46) 46
French (33) 33
Japanese (30) 30
Chinese (27) 27
Spanish (12) 12
Russian (8) 8
Hungarian (4) 4
Czech (3) 3
Dutch (3) 3
Bulgarian (2) 2
Korean (2) 2
Polish (2) 2
Swedish (2) 2
Croatian (1) 1
Danish (1) 1
Finnish (1) 1
Lithuanian (1) 1
Norwegian (1) 1
Serbian (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2159 - 2167
OBJECTIVE To compare the efficacy and safety of dulaglutide, a once-weekly GLP-1 receptor agonist, with placebo and exenatide in type 2 diabetic patients. The... 
GLYCEMIC CONTROL | GLUCAGON-LIKE PEPTIDE-1 | EXENDIN-4 | SITAGLIPTIN | ENDOCRINOLOGY & METABOLISM | ANALOG LIRAGLUTIDE | OPEN-LABEL | LY2189265 | TREATED PATIENTS | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Male | Immunoglobulin Fc Fragments - administration & dosage | Thiazolidinediones - administration & dosage | Metformin - adverse effects | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Metformin - administration & dosage | Drug Therapy, Combination | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Venoms - adverse effects | Hypoglycemia - drug therapy | Thiazolidinediones - adverse effects | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Type 2 diabetes | Care and treatment | Safety and security measures | Dosage and administration | Metformin | Comparative analysis | Exenatide | Clinical trials | Hemoglobin | Diabetes | Product safety | Drug dosages | Placebo effect | Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2010, Volume 376, Issue 9739, pp. 431 - 439
Journal Article
Diabetes Care, ISSN 0149-5992, 2014, Volume 37, Issue 8, pp. 2317 - 2325
Journal Article
Diabetes Care, ISSN 0149-5992, 02/2012, Volume 35, Issue 2, pp. 252 - 258
Journal Article
ANNALS OF INTERNAL MEDICINE, ISSN 0003-4819, 01/2011, Volume 154, Issue 2, pp. 103 - 103
Background: Insulin replacement in diabetes often requires prandial intervention to reach hemoglobin A(1c) (HbA(1c)) targets. Objective: To test whether... 
NPH INSULIN | MEDICINE, GENERAL & INTERNAL | GLYCEMIC CONTROL | ORAL-THERAPY | ADD-ON | GLUCOSE-LOWERING DRUGS | COMBINATION THERAPY | PARALLEL-GROUP | NAIVE PEOPLE | OPEN-LABEL | TO-TARGET TRIAL | Metformin - therapeutic use | Glycated Hemoglobin A - metabolism | Humans | Middle Aged | Body Weight - drug effects | Male | Thiazolidinediones - administration & dosage | Peptides - administration & dosage | Thiazolidinediones - therapeutic use | Hypoglycemic Agents - administration & dosage | Injections, Subcutaneous | Sensitivity and Specificity | Venoms - administration & dosage | Female | Insulin - analogs & derivatives | Metformin - administration & dosage | Drug Therapy, Combination | Hypoglycemic Agents - therapeutic use | Insulin, Long-Acting | Double-Blind Method | Drug Administration Schedule | Venoms - adverse effects | Insulin - administration & dosage | Diabetes Mellitus, Type 2 - blood | Insulin Glargine | Venoms - therapeutic use | Aged | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Insulin - therapeutic use | Peptides - adverse effects | Peptides - therapeutic use | Type 2 diabetes | Glycosylated hemoglobin | Physiological aspects | Research | Diagnosis | Drug therapy | Injections | Side effects | Clinical trials | Diabetes | Hypoglycemia | Insulin | Weight | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2014, Volume 16, Issue 5, pp. 467 - 477
Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM)... 
thiazolidinediones | metformin | type 2 diabetes | phase 3 study | inhibitor | SGLT2 | Type 2 diabetes | Metformin | Phase 3 study | SGLT2 inhibitor | Thiazolidinediones | GLYCEMIC CONTROL | PLACEBO | ADD-ON | SULFONYLUREA | MONOTHERAPY | SITAGLIPTIN | BODY-WEIGHT | ENDOCRINOLOGY & METABOLISM | COTRANSPORTER 2 INHIBITOR | PANCREATIC-FUNCTION | Thiophenes - therapeutic use | Triazoles - administration & dosage | Thiophenes - adverse effects | Humans | Middle Aged | Pyrazines - administration & dosage | Lipids | Male | Thiophenes - administration & dosage | Genital Diseases, Female - chemically induced | Thiazolidinediones - administration & dosage | Hypoglycemic Agents - administration & dosage | Female | Glucosides - therapeutic use | Blood Pressure - drug effects | Metformin - administration & dosage | Sitagliptin Phosphate | Drug Therapy, Combination | Candidiasis - chemically induced | Glucosides - adverse effects | Hypoglycemic Agents - therapeutic use | Diuretics, Osmotic - adverse effects | Double-Blind Method | Genital Diseases, Male - chemically induced | Treatment Outcome | Blood Glucose - drug effects | Diabetes Mellitus, Type 2 - blood | Canagliflozin | Glucosides - administration & dosage | Weight Loss | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Glucose metabolism | Care and treatment | Analysis | Low density lipoproteins | Hemoglobin | Glucose | Dextrose | Drug therapy | Diabetes | Index Medicus | Original
Journal Article
American Journal of Medicine, The, ISSN 0002-9343, 2012, Volume 125, Issue 3, pp. 302.e1 - 302.e7
Abstract Objective Six oral medication classes have been approved by the Food and Drug Administration for the treatment of type 2 diabetes. Although all of... 
Internal Medicine | Pharmacotherapy | Diabetes | Cost-effectiveness | Quality of care | STATEMENT | EUROPEAN-ASSOCIATION | MANAGEMENT | MYOCARDIAL-INFARCTION | RISK | ADJUSTMENT | MEDICINE, GENERAL & INTERNAL | HYPERGLYCEMIA | CONSENSUS ALGORITHM | ROSIGLITAZONE | Metformin - therapeutic use | Hypoglycemic Agents - economics | United States | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Humans | Middle Aged | Male | Thiazolidinediones - administration & dosage | Sulfonylurea Compounds - economics | Dipeptidyl-Peptidase IV Inhibitors - economics | Metformin - economics | Practice Patterns, Physicians' - statistics & numerical data | Thiazolidinediones - therapeutic use | alpha-Glucosidases - therapeutic use | Hypoglycemic Agents - administration & dosage | Aged, 80 and over | Adult | Female | alpha-Glucosidases - economics | Sulfonylurea Compounds - administration & dosage | Metformin - administration & dosage | Hypoglycemic Agents - therapeutic use | Administration, Oral | Sulfonylurea Compounds - therapeutic use | Logistic Models | Thiazolidinediones - economics | Evidence-Based Medicine | Dipeptidyl-Peptidase IV Inhibitors - administration & dosage | alpha-Glucosidases - administration & dosage | Adolescent | Aged | Diabetes Mellitus, Type 2 - drug therapy | Quality of Health Care | Type 2 diabetes | Prices and rates | Hypoglycemic agents | Dosage and administration | Research | Drug therapy | Medical care, Cost of | Diabetes therapy | Health care expenditures | Medical diagnosis | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes Care, ISSN 0149-5992, 04/2017, Volume 40, Issue 4, pp. 468 - 475
Journal Article
CA Cancer Journal for Clinicians, ISSN 0007-9235, 07/2010, Volume 60, Issue 4, pp. 207 - 221
Epidemiologic evidence suggests that cancer incidence is associated with diabetes as well as certain diabetes risk factors and treatments. This consensus... 
LIFE-STYLE INTERVENTION | GLYCEMIC INDEX | INSULIN-RECEPTOR | ACTIVATED RECEPTOR-GAMMA | ONCOLOGY | COLORECTAL-CANCER | BODY-MASS INDEX | PPAR-GAMMA | FACTOR-BINDING PROTEIN-1 | PHYSICAL-ACTIVITY | NEGATIVE BREAST-CANCER | Neoplasms - metabolism | Smoking - adverse effects | Receptor, IGF Type 1 - metabolism | Diabetes Complications | Neoplasms - etiology | Age Factors | Humans | Hyperglycemia - complications | Alcohol Drinking | Motor Activity | Thiazolidinediones - administration & dosage | Estrogens - blood | Metformin - adverse effects | Overweight | Neoplasms - complications | Hypoglycemic Agents - administration & dosage | Sulfonylurea Compounds - administration & dosage | Insulin - analogs & derivatives | Metformin - administration & dosage | Testosterone - blood | Continental Population Groups | Body Mass Index | Hyperinsulinism - complications | Cytokines - metabolism | Risk Factors | Diabetes Mellitus - drug therapy | Insulin - administration & dosage | Sulfonylurea Compounds - adverse effects | Thiazolidinediones - adverse effects | Diet | Incretins - adverse effects | Sex Factors | Receptor, Insulin - metabolism | Hypoglycemic Agents - adverse effects | Insulin - adverse effects | Incretins - administration & dosage | Complications and side effects | Care and treatment | Diabetes | Risk factors | Cancer | Diabetes therapy | Experts | Epidemiology | Medical prognosis | Index Medicus | Abridged Index Medicus
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 07/2015, Volume 17, Issue 7, pp. 665 - 674
Journal Article
Journal Article